135 related articles for article (PubMed ID: 33553338)
1. Roles of NANOGP8 in cancer metastasis and cancer stem cell invasion during development of castration-resistant prostate cancer.
Sui Y; Zhang W; Zhu R; Gao L; Cao T; Chen C; Gong M; Zhu H; Tang T; Yu B; Yang T
Ann Transl Med; 2021 Jan; 9(1):45. PubMed ID: 33553338
[TBL] [Abstract][Full Text] [Related]
2. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.
Jeter CR; Liu B; Liu X; Chen X; Liu C; Calhoun-Davis T; Repass J; Zaehres H; Shen JJ; Tang DG
Oncogene; 2011 Sep; 30(36):3833-45. PubMed ID: 21499299
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells.
Kawamura N; Nimura K; Nagano H; Yamaguchi S; Nonomura N; Kaneda Y
Oncotarget; 2015 Sep; 6(26):22361-74. PubMed ID: 26087476
[TBL] [Abstract][Full Text] [Related]
4. Transgenic overexpression of NanogP8 in the mouse prostate is insufficient to initiate tumorigenesis but weakly promotes tumor development in the Hi-Myc mouse model.
Liu B; Gong S; Li Q; Chen X; Moore J; Suraneni MV; Badeaux MD; Jeter CR; Shen J; Mehmood R; Fan Q; Tang DG
Oncotarget; 2017 Aug; 8(32):52746-52760. PubMed ID: 28881767
[TBL] [Abstract][Full Text] [Related]
5. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Kregel S; Szmulewitz RZ; Vander Griend DJ
Prostate; 2014 Nov; 74(15):1530-43. PubMed ID: 25175748
[TBL] [Abstract][Full Text] [Related]
6. Activated 5'flanking region of NANOGP8 in a self-renewal environment is associated with increased sphere formation and tumor growth of prostate cancer cells.
Zhang K; Fowler M; Glass J; Yin H
Prostate; 2014 Apr; 74(4):381-94. PubMed ID: 24318967
[TBL] [Abstract][Full Text] [Related]
7. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer.
Le TT; Hsieh CL; Lin IH; Chu CY; Do AD; Chen SH; Shigemura K; Kitagawa K; Fujisawa M; Liu MC; Chen KC; Sung SY
Am J Cancer Res; 2022; 12(1):176-197. PubMed ID: 35141012
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
[TBL] [Abstract][Full Text] [Related]
9. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
[TBL] [Abstract][Full Text] [Related]
12. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
[TBL] [Abstract][Full Text] [Related]
13. NANOG modulates stemness in human colorectal cancer.
Zhang J; Espinoza LA; Kinders RJ; Lawrence SM; Pfister TD; Zhou M; Veenstra TD; Thorgeirsson SS; Jessup JM
Oncogene; 2013 Sep; 32(37):4397-405. PubMed ID: 23085761
[TBL] [Abstract][Full Text] [Related]
14. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
16. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.
Seiler D; Zheng J; Liu G; Wang S; Yamashiro J; Reiter RE; Huang J; Zeng G
Prostate; 2013 Sep; 73(13):1378-90. PubMed ID: 23728788
[TBL] [Abstract][Full Text] [Related]
17. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
20. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
